Molecular Markers in the Era of Precision Care in Lung Cancer.

IF 2.3 3区 医学 Q2 CRITICAL CARE MEDICINE
Ishan Paranjpe, Alexander Salter, Kenneth Chen, Millie Das
{"title":"Molecular Markers in the Era of Precision Care in Lung Cancer.","authors":"Ishan Paranjpe, Alexander Salter, Kenneth Chen, Millie Das","doi":"10.1055/a-2649-9199","DOIUrl":null,"url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The past two decades have brought advances in molecular profiling and the advent of therapies that specifically target genetic and/or molecular alterations in NSCLC. There are now many FDA-approved targeted therapies for patients with metastatic lung cancer who harbor oncogenic driver alterations, including those in EGFR, ALK, KRAS, MET, and others. These advances epitomize personalized medicine and are improving patient outcomes compared to conventional cytotoxic chemotherapy. This review highlights the current and evolving landscape of targeted therapies in NSCLC, emphasizing key molecular targets, resistance mechanisms, and new approaches poised to improve patient outcomes in the era of precision oncology. The next decade will likely be marked by further improvements in the specificity, duration of action, and toxicity profiles of targeted therapies, which will allow patients to live longer and better lives.</p>","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2649-9199","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The past two decades have brought advances in molecular profiling and the advent of therapies that specifically target genetic and/or molecular alterations in NSCLC. There are now many FDA-approved targeted therapies for patients with metastatic lung cancer who harbor oncogenic driver alterations, including those in EGFR, ALK, KRAS, MET, and others. These advances epitomize personalized medicine and are improving patient outcomes compared to conventional cytotoxic chemotherapy. This review highlights the current and evolving landscape of targeted therapies in NSCLC, emphasizing key molecular targets, resistance mechanisms, and new approaches poised to improve patient outcomes in the era of precision oncology. The next decade will likely be marked by further improvements in the specificity, duration of action, and toxicity profiles of targeted therapies, which will allow patients to live longer and better lives.

肺癌精准护理时代的分子标记。
非小细胞肺癌(NSCLC)是全球癌症相关死亡的主要原因。在过去的二十年中,分子谱分析取得了进展,并且出现了专门针对非小细胞肺癌遗传和/或分子改变的治疗方法。现在有许多fda批准的靶向治疗转移性肺癌患者的致癌驱动改变,包括那些在EGFR, ALK, KRAS, MET等。这些进步是个性化医疗的缩影,与传统的细胞毒性化疗相比,正在改善患者的预后。本综述重点介绍了NSCLC靶向治疗的现状和发展趋势,强调了关键的分子靶点、耐药机制和在精准肿瘤学时代有望改善患者预后的新方法。未来十年,靶向治疗的特异性、作用持续时间和毒性特征可能会进一步改善,这将使患者活得更长、更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
87
审稿时长
6-12 weeks
期刊介绍: The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信